Hayden E. Klein

The new indication allows doctors to use upadacitinib before tumor necrosis factor–blocking agents when those treatments are clinically inadvisable.

Lindsey Valenzuela, PharmD, explains how pharmacists can prevent drug interactions and improve coordination for women with arrhythmia and chronic disease.

Lindsey Valenzuela, PharmD, explains how cost, coverage gaps, and tech literacy hinder women’s access to early arrhythmia detection tools.

Lindsey Valenzuela, PharmD, explains how atypical symptoms, research gaps, and care inequities delay arrhythmia detection in women.

Laxmi Patel of Savista discusses how the Budget Reconciliation Act could widen Medicaid coverage gaps and strain hospitals across states.

A CCS report found that pharmacists lack time for diabetes education as workloads rise, worsening disparities and threatening adherence.

Research highlights disparities in anti-obesity medication use and metabolic and bariatric surgery.

The European Association for the Study of Obesity now recommends the 2 treatments for obesity and most associated complications.

The risk of pneumonia-related hospitalization increased the most for patients using non-TNFi biologics, climbing by 257% compared with controls.

Immune gene signatures were linked to illness severity and treatment response in sepsis and other critical conditions.

Hope Krebill of the Masonic Cancer Alliance at the University of Kansas Medical Center outlines patient navigation models that improve outcomes and reduce missed appointments.

Cardiopulmonary risk is high and persistent across the entire COPD disease course, making early recognition and integrated care crucial.

Laxmi Patel urges rural hospitals to align leadership early and build logic models to show how transformation funds can drive access, equity, and sustainability.

Hope Krebill, MSW, BSN, RN, discusses the challenges rural hospitals face in delivering therapies like CAR T and bispecifics.

Laxmi Patel explains how providers can meet potential new Medicaid documentation requirements without harming patient access.

Altering gut motility, fueling inflammation, and disturbing microbes are some of the ways stress and anxiety can disrupt gut health.

Laxmi Patel urges hospitals to embed financial screening and simplify payment options to prepare for rising levels of uninsured patients from Medicaid changes.

The program works by embedding Medbridge’s Pathways platform into Marathon’s MoveWell MSK program and advanced primary care model.

Researchers found that even smaller open artificial intelligence (AI) models outperformed clinicians, supporting automation of International Classification of Disease (ICD) coding.

From proactive recruitment to academic-community partnerships, Hope Krebill highlights ways to improve clinical trial participation.

The relationship between caffeine and rheumatoid arthritis has been inconsistent across prior studies.

These patients had a higher spleen-to-liver stiffness ratio than those with alcohol-related liver disease, warranting a closer look at testing.

Laxmi Patel outlines how Medicaid reforms could raise bad debt, urging providers to strengthen financial counseling, assistance, and price transparency.

Laxmi Patel explains how Medicaid reforms could increase uncompensated care and the burden on hospitals, and how technology can help automate workflows.

Research shows more than a third of patients with rheumatoid arthritis met criteria for frailty, with prefrailty and robust groups closely following.

Laxmi Patel discusses proposed Medicaid reforms in HR 1, including work rules, coverage limits, and state-level risks for vulnerable populations.

By 2040, advanced metabolic dysfunction–associated steatohepatitis (MASH) is projected to rise by at least 20% in the 9 countries assessed.

From 2017 to 2023, women were especially underrepresented in trials in arrhythmia, coronary heart disease, acute coronary syndrome, and heart failure.

The drug lowered inflammation, oxidative stress, and endothelial injury markers in women with INOCA and coronary microvascular dysfunction.

Pulse of the Purchaser 2025 survey results showed the use of transparent PBMs more than doubled in just 1 year, from 12% to 31%.